Member Info for Nolupus

Twitter is for Twits and for the pump & dump crowds , imv

Rich,

Without wanting to ramp up Tils where I am invested also , they have a non COvid pipeline and patents which are just extrodinary and very very promising imv

As said this morning the COvid angle is pertinent with the anti -il6 approch but as you say they are behind in the timescale and I agree ...
But I would definetly be keeping an eye out the rear view mirror on what they are up to !

Wellcome CW25 ...

Bring on those TR-1 's so we can talk about SNG , sherif

Punit,

TILS is the most promising Biotech in Britain and maybe even in Europe in my opinion .
The next 6 months will be very eventful , imo

Although, I consider TILS as being the U.K. Best pipeline in a biotech , I think that they are a little bit behind the flock with covid 19 .

I would love to see a combo treatment with SNG001 and TLS -501 but

https://www.fenews.co.uk/fevoices/50261-government-to-protect-uk-research-jobs-with-280-million-support-package

Andle,

I agree with that :-)

Let's hope that we will see great rewards :-)

Anybody notice the movement on their Sp :-)

Gkb47,
Too many cooks ...

Time for a break ...

Fine tuning the immune system with interferons ... boost when needed and slow down the system when necessary ...

Wonder where we heard that before ?

Must have been Richy :-)

Thanks to sharing the article but once again one should not interpret what happens with the different types of interferons in covid19 research .
All interferon have different fonctions in regards to the immune system .

Here the research is interferon lambda and not interferon beta which Synairgen use .

Jollyspeculator,

I think we have run out of time to go back to 10-12p personally ... I think we would have gone there before now if That was the plan ...
My view is that the newsflow is imminent but wtf do I know ...

I won't say yes and I won't say no :-)

The message is clear ....

Yes , if we don't sign a partnership on the back of our readouts ....

No , of we do sign up ...

The strategy seems to be different to what I had initially envisaged which was a partnership signing on the COPD results ...
My interpretation is now that Richard is looking to do a P3 trial in COPD In house whilst signing a partnership or a sale of the Rights to SNG001 in Covid to a major ...
Only my thoughts but the focus is firmly put on the covid hospital readout , imv

@antofelli,

The endpoints are different in both trials

Here is the link for the covid19 trial so you can check the primary and secondary endpoints ...

https://clinicaltrials.gov/ct2/show/NCT04385095

@antofelli

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881606/

RICH ,

You're nagging again ....

I never said it was'nt relevant , I just said it was a secondary endpoint for the clinical trial and not a primary endpoint !

It's the attainment of primary endpoint which dictate if a trial is a success or not ....

Rich ,
Is that the same link that I posted below ?? :-))

https://clinicaltrials.gov/ct2/show/NCT03570359?term=Synairgen&draw=1&rank=2

Rich ... BCSS is only a secondary endpoint

To be deemed a success , the primary endpoints have to be met ...

For those not in th know of COPD endpoints

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131613/

Endpoints

https://clinicaltrials.gov/ct2/show/NCT03570359?term=Synairgen&draw=1&rank=2